Cargando…
The Impact of Omitting 5-FU Bolus From mFOLFOX6 Chemotherapy Regimen on Hematological Adverse Events Among Patients With Metastatic Colorectal Cancer
BACKGROUND: Metastatic colorectal cancer (mCRC) is often treated with a mFOLFOX6 regimen. The 5-fluorouracil (5-FU) bolus is often omitted from the regimen to reduce the risk of hematological adverse events (AEs) in patients with poor performance status. We aimed to investigate the incidence of hema...
Autores principales: | Areepium, Nutthada, Sapapsap, Bannawich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588498/ https://www.ncbi.nlm.nih.gov/pubmed/37869236 http://dx.doi.org/10.14740/wjon1690 |
Ejemplares similares
-
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013) -
Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
por: Matsunaga, Mototsugu, et al.
Publicado: (2016) -
mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma
por: Matsunaga, Mototsugu, et al.
Publicado: (2016) -
The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019) -
Disturbance of consciousness due to hyperammonemia and lactic acidosis during mFOLFOX6 regimen: Case report
por: Fukuda, Masafumi, et al.
Publicado: (2020)